THERAPY OF INHIBITED PARANOID PRESCHIZOPHRENIA Russian patent published in 2009 - IPC A61M1/38 A61K31/5513 A61K31/4412 A61K35/26 A61G10/02 A61P25/18 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to psychiatry, and can be used for treatment of patients suffering from a first episode of schizophrenia. The therapy involves single session of plasmapheresis by discrete method on the first day. Starting from the second day within 40 days, diazepam 0.5% is injected intramuscularly in a dose 2-2.5 ml 3 times a day during 2 to 21 day and in the same dose twice a day in the following days, in combination with Mexidol in a daily dose 600-800 mg introduced intravenously drop-by-drop two-intake within 10-12 days, for the following 10 days intravenously drop-by-drop in a dose 300-400 mg two-intake and 250-375 mg orally tableted two-intake until termination of the therapy. Thymogen 0.01% is introduced in a dose 1-1.2 ml intramuscularly every second day, 15 injections totally. On the 30^th day of treatment, single dose 35-40 mg of prolonged Fluanxol. Said pharmacotherapy is combined with hyperbaric oxygenation of excess pressure 0.8-1.0 atmosphere at compression and decompression rate 0.1 atmospheres per minute and isopression period 40 minutes twice a day within the first 20 days and once a day within the next 20 days.

EFFECT: method allows ensuring reductions of cardinal psychopathological symptoms due to integrated effect on neuroendocrine and immune regulative components of mental functions.

1 ex